174 related articles for article (PubMed ID: 30355760)
21. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.
Cuschieri K; Cubie H; Graham C; Rowan J; Hardie A; Horne A; Earle CB; Bailey A; Crosbie EJ; Kitchener H
J Clin Virol; 2014 Feb; 59(2):104-8. PubMed ID: 24380720
[TBL] [Abstract][Full Text] [Related]
22. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
23. Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China.
Zhang J; Yang D; Cui X; Liu G; Cui Z; Wang C; Piao H
Front Cell Infect Microbiol; 2022; 12():935071. PubMed ID: 36105144
[TBL] [Abstract][Full Text] [Related]
24. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
[TBL] [Abstract][Full Text] [Related]
25. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
26. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
[TBL] [Abstract][Full Text] [Related]
27. Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study.
Castle PE; Cuzick J; Stoler MH; Wright TC; Reid JL; Dockter J; Giachetti C; Getman D
Am J Clin Pathol; 2015 Feb; 143(2):160-7. PubMed ID: 25596241
[TBL] [Abstract][Full Text] [Related]
28. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results.
Stoler MH; Wright TC; Cuzick J; Dockter J; Reid JL; Getman D; Giachetti C
Am J Obstet Gynecol; 2013 Feb; 208(2):144.e1-8. PubMed ID: 23220509
[TBL] [Abstract][Full Text] [Related]
29. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
30. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
31. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
32. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
[TBL] [Abstract][Full Text] [Related]
33. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
34. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
35. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.
Castle PE; Lorincz AT; Scott DR; Sherman ME; Glass AG; Rush BB; Wacholder S; Burk RD; Manos MM; Schussler JE; Macomber P; Schiffman M
J Clin Microbiol; 2003 Sep; 41(9):4022-30. PubMed ID: 12958220
[TBL] [Abstract][Full Text] [Related]
36. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
[TBL] [Abstract][Full Text] [Related]
37. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
[TBL] [Abstract][Full Text] [Related]
38. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India.
Anand KV; Pimple SA; Bhattacharjee A; Mishra GA; Shastri SS
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2709-2716. PubMed ID: 34452578
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
Wang J; Du Y; Dong J; Zhou Y; Wang P; Zhang X; Chen Y; He P
Gynecol Oncol; 2019 Apr; 153(1):34-40. PubMed ID: 30630629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]